Skip to main content
. Author manuscript; available in PMC: 2015 Nov 6.
Published in final edited form as: Mol Cancer Res. 2014 Apr 25;12(7):979–986. doi: 10.1158/1541-7786.MCR-14-0158-T

Figure 1. Combined thyrocyte-specific expression of BRAFV600E and PIK3CAH1047R result in lethal thyroid carcinogenesis.

Figure 1

A: Kaplan-Meier survival curves comparing mice survival of tamoxifen-treated Thyro::CreER; BRafCA/+; Pik3caLat/+ and Thyro::CreER; BRafCA/+ mice (**: P≤0.01; Log-Rank Test)

B: Thyroid tumor burden in tamoxifen-treated Thyro::CreER; BRafCA/+; Pik3caLat-HR/+ andThyro::CreER; BRafCA/+ mice measured by ultrasonography (**: P≤0.01; t-Test) 2.5 months after tumor induction.

C: H&E staining of histological section of thyroid from control BRafCA/+ (WT): Thyro::CreER; BRafCA/+(BRAFV600E) and Thyro::CreER; Pik3caLat/+ (PI3KCAH1047R) mice, at 40× (Upper row) and 200× (Lower row) magnification.

D: H&E staining of histological section of thyroid Thyro::CreER; BRafCA/+; Pik3caLat/+ (BRAFV600E PI3KCAH1047R) showing an area of PTC (Left), tracheal airway invasion (Middle) and ATC area (Right), at 40× (Upper row) and 200× (Lower row) magnification.